UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006744 |
|---|---|
| Receipt number | R000007969 |
| Scientific Title | Phase I/II study of bexarotene capsule (BSC-1) in patients with Cutaneous T-cell Lymphoma (CTCL) |
| Date of disclosure of the study information | 2011/12/01 |
| Last modified on | 2016/04/07 16:28:48 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase I/II study of bexarotene capsule (BSC-1) in patients with Cutaneous T-cell Lymphoma (CTCL)
Acronym
Phase I/II study of bexarotene capsule (BSC-1) in patients with Cutaneous T-cell Lymphoma (CTCL)
Scientific Title
Phase I/II study of bexarotene capsule (BSC-1) in patients with Cutaneous T-cell Lymphoma (CTCL)
Scientific Title:Acronym
Phase I/II study of bexarotene capsule (BSC-1) in patients with Cutaneous T-cell Lymphoma (CTCL)
Region
| Japan |
Condition
Condition
Cutaneous T-Cell Lymphoma
Classification by specialty
| Dermatology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Phase I:
To evaluate the tolerability and pharmacokinetics of 150 mg/m2/day or 300 mg/m2/day of bexarotene capsules in Japanese patients with cutaneous T-cell lymphoma (CTCL).
Phase II:
To evaluate the efficacy, safety and tolerability of 300 mg/m2/day bexarotene capsules in Japanese patients with CTCL.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Phase I,II
Assessment
Primary outcomes
Primary efficacy endopoint:
-Modified Severity-weighted Assessment Tool (mSWAT)
-Physician's Global Assessment (PGA)
-Composite Assessment of Index Lesion Disease Severity (CA)
-abnormal lymph nodes, cutaneous tumors, visceral disease
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
NO
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Patients enrolled in phase 1 were treated in sequential cohorts of patients and orally administered bexarotene at a dose level of 150 mg/m2 or 300 mg/m2 once daily within 30 minutes of a meals for 4 weeks.In the phase 2 study, patients were orally administered a 300 mg/m2 dose of bexarotene once daily within 30 minutes of a meal for 24 weeks.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. A clinical diagnosis of cutaneous T-cell lymphoma, CTCL, confirmed by biopsy to be histologically consistent with CTCL diagnosis by a dermatopathologist. stage IIB-IV, stage IB-IIA with refractory to at least one systemic therapy for CTCL.
2. Age>=20 years.
3. Eastern Cooperative Oncology Group, ECOG, performance status Performance Status 0-2
4. Adequate abdominal function as below. A. Adequate renal function as evidenced by serum creatinine =<2.0 mg/dL, or calculated creatinine clearance >=40 mL/min as per the Cockroft and Gault formula. B. Adequate hepatic function that is characterized by aspartate aminotransferase (AST), alanine aminotransferase (ALT), or serum bilirubin more than 2.5 times the upper limit of normal. C. Adequate bone marrow function as evidenced by hemoglobin more than 8 g/dL, absolute neutrophil count more than 1,000/mm3, and platelets more than 50,000/mm3.
5. Fasting serum triglyceride within normal limits, <150 mg/dL, or in treatment with anti-dyslipidaemia. prior to study entry.
6. Females of childbearing potential must have a negative serum beta human chorionic gonadotropin within seven days prior to the initiation of treatment, and must have used highly effective methods of contraception for at least 4 weeks prior to the negative pregnancy test through entry to the study.
7. Male patients with female partners of childbearing potential must agree to practice the effective contraception during the entire period of bexarotene capsule treatment and for at least 1 month after treatment is discontinued.
8. Must be willing and able to give informed consent, complete and understand, either oral or written, study procedures and assessments.
Key exclusion criteria
1. Cutaneous T-cell lymphoma involving the central nervous system
2. Subjects with known adult T-cell leukemia/lymphoma
3. Systemic antibiotic therapy within 2 weeks of entry in the study
4. Topical CTCL therapy, regional chemotherapy, topical steroid and other, within 2 weeks of entry the study
5. PUVA or UVB therapy within 3 weeks
6. Radiation therapy within 4 weeks of entry to the study
7. Systemic anticancer therapy of any kind within 4 weeks of entry to the study
8. Systemic therapy with Vitamin A in doses of greater than 15,000 IU, 5,000 mcg, per day within 4 weeks of entry to the study
9. Received systemic steroids within 4 weeks of entry in the study
10. Participation in any other investigational drug study within 12 week of entry in this study
11.Received Etretinate therapy within one year of entry in the study
12. Patients with pregnancy, intent to become pregnant, breast-feeding or unwillingness to effective contraception.
13. Subjects have critical intercurrent illness or serious infection diseases
14. History of pancreatitis or significant risk factors for developing pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity
15. Known or suspected hypersensitivity to bexarotene or any other retinoid preparations
16. Known serious allergic reaction or critical hypersensitivity to drugs
17. Unwillingness or inability to minimize exposure to sunlight and artificial ultraviolet light
18. Principal investigator judged inadequate
Target sample size
16
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Hideo Inoue |
Organization
Research and Development Division
Division name
Reserch Laboratory
Zip code
Address
2-2-3, Komatsubara, Zama-shi, Kanagawa
TEL
0359090027
t_yoshida@minophagen.co.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tsuyoshi Yoshida |
Organization
Minophagen Pharmaceutical Co. Ltd
Division name
Regulatory Compliance Department
Zip code
Address
3-2-11, Nishi-Shinjuku, Shinjuku-ku, Tokyo
TEL
03-5909-0029
Homepage URL
t_yoshida@minophagen.co.jp
Sponsor or person
Institute
Minophagen Pharmaceutical Co. Ltd.
Institute
Department
Personal name
Funding Source
Organization
Minophagen Pharmaceutical Co. Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
福島県立医科大学附属病院（福島県）、東京大学医学部附属病院（東京都）、東京医科大学病院（東京都）、東京医科大学八王子医療センター（東京都）、浜松医科大学（静岡県）、大阪大学病院（大阪府）、岡山大学病院（岡山県）、宮崎大学医学部附属病院（宮崎県）、鹿児島大学医学部・歯学部附属病院（鹿児島県）、今村病院分院（鹿児島県）
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 12 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 10 | Month | 20 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 01 | Month | 01 | Day |
Last follow-up date
| 2013 | Year | 12 | Month | 27 | Day |
Date of closure to data entry
| 2014 | Year | 04 | Month | 23 | Day |
Date trial data considered complete
| 2014 | Year | 07 | Month | 11 | Day |
Date analysis concluded
| 2014 | Year | 11 | Month | 06 | Day |
Other
Other related information
Management information
Registered date
| 2011 | Year | 11 | Month | 18 | Day |
Last modified on
| 2016 | Year | 04 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007969
